Ontinua ER FDA Approval Status
FDA Approved: No
Brand name: Ontinua ER
Generic name: arbaclofen
Dosage form: Extended-Release Tablets
Company: Osmotica Pharmaceuticals plc
Treatment for: Spasticity, Multiple Sclerosis
Ontinua ER (arbaclofen) is a prodrug of R-baclofen in devleopment for the treatment of spasticity associated with multiple sclerosis.
Development timeline for Ontinua ER
| Date | Article |
|---|---|
| Sep 28, 2015 | Osmotica Announces FDA Acceptance of Filing for Ontinua ER for Alleviation of Spasticity Resulting from Multiple Sclerosis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
